Cancer Care Updates ‘Helping Hand’ Guide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 5
Volume 7
Issue 5

NEW YORK--Cancer Care, Inc. has just released the second edition of A Helping Hand: The Resource Guide for People with Cancer, with support from Zeneca Pharmaceuticals. The handbook is designed to show newly diagnosed cancer patients the kind of help that is available and where it can be found.

NEW YORK--Cancer Care, Inc. has just released the second edition of A Helping Hand: The Resource Guide for People with Cancer, with support from Zeneca Pharmaceuticals. The handbook is designed to show newly diagnosed cancer patients the kind of help that is available and where it can be found.

The second edition has updated listings, new sections (for example, on how to use the Internet to find information), and a wealth of information on national, regional, and local cancer-related organizations that provide critically important services for people with cancer.

Cancer Care, Inc. is the largest agency in the nation dedicated solely to providing support for cancer patients and their families and friends, as well as education for the general public. The first copy of the resource guide is available free of charge through the agency’s toll-free counseling line at 1-800-813-HOPE (4673) or through a Zeneca sales rep.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content